Back to results
US 7,696,185 B2Granted
Peptidomimetic inhibitors of PSMA, compounds comprising them, and methods of use
AssigneeCancer Targered Technology LLC
InventorCliff Berkman
Life of this patent
Estimating the term…
Abstract
Compounds of the formula, A—L—B, wherein A is glutamate or a glutamate analog; L is a phosphoramidate or a phosphoramidate analog; and B is serine or a serine analog are described which are potent inhibitors of prostate-specific membrane antigen (PMSA). Such compounds are useful in treatment of prostate cancer; and when chemically attached to a fluorescent dye, can efficiently and selectively label prostate cancer cells for fluorescent imaging.
Claims20
The compound or pharmaceutically acceptable salt thereof, of the formula,
- wherein
- each n is independently 1, 2, 3, 4, 5 or 6;
- each R1 and R2 are independently —C(O)OR3, —C(O)N(R3)2, —P(O)(OR3)2, —OP(O)(OR3)2, —S(O)2R3, —S(O)2OR3, —S(O)2N(R3)2, or tetrazolyl;
- each R3 is independently —H or C1-C6 alkyl;
- R4 is —H, —C(O)OR3, —C(O)N(R3)2, —P(O)(OR3)2, —OP(O)(OR3)2, —S(O)2R3, —S(O)2OR3, —S(O)2N(R3)2, or tetrazolyl;
- L is —P(O)(OR3)—, or —P(O)(N(R3)2)—;
- M and T are independently —O—, —S—, —N(R3)—, or —CH2—;
- R10 is —H, —C1-C6 alkyl, aryl, —C1-C6 alkyl-aryl, -aryl-aryl, —X—R6, —R7, —C(O)R5, —S(O)2R5, peptide, dendrimer, or peptide dendrimer, wherein
- X is —O—, —S—, or —N(R3)—;
- R5 is —CH(R51)N(R52)2;
- C1-C6 alkyl optionally substituted with 1 to 3 groups which are independently -halogen, COOR53, or —N(R52)2;
- aryl;
- or heteroaryl, wherein
- R51 is —H, aryl, heteroaryl, C1-C6 alkyl-aryl optionally substituted with —OH;
- C1-C6 alkyl-heteroaryl, or C1-C6 alkyl optionally substituted with —OR53, —SR53, —NH2, —N(H)C(═NH)NH2, —COOR53, or —C(O)N(R53)2;
- and
- R52 is —H, C1-C6alkyl, —C(O)R53, C(O)OR53, —C(O)NH(C1-C6alkyl), —C(O)N(R53)2, —C(O)aryl, or —C(O)heteroaryl;
- R53 is —H, C1-C6alkyl, or C1-C6 alkyl-aryl;
- R6 is —H or C1-C6 alkyl;
- and
- R7 is —L1—R8, wherein
- L1 is —C(O)N(R3)—, —C(S)N(R3)—, —C(O)CH(R21)—, —C(O)(O), or —C(O)—L2—,
- wherein
- R21 is —H, aryl, heteroaryl, C1-C6 alkyl-aryl optionally substituted with —OH;
- C1-C6 alkyl-heteroaryl, or C1-C6 alkyl optionally substituted with —OR23, —SR23, —NH2, —N(H)C(═NH)NH2, —COOR23, or —C(O)N(R23)2;
- and
- R23 is —H, C1-C6alkyl, or C1-C6 alkyl-aryl;
- L2 is —C1-C24 alkyl- or -phenyl-C1-C24 alkyl-, wherein
- each alkyl group is optionally substituted with 1 to 4 groups which are oxo, ═S, or —COOH;
- and
- one to six of the methylene groups in each alkyl group is optionally replaced by —O—, —S—, or —N(R3)—, provided that no two adjacent methylene groups are both replaced by —O—, —S—, or —N(R3)—;
- and
- R8 is —H, —NH2, or —OH;
- and
- Q is —O—, —S—, —N(R3)—, —N(R3)O—, —ON(R3)—, —CH2—, or ═NO—.
32 more elements
The compound or pharmaceutically acceptable salt thereof of the formula,
- wherein
- each n is independently 1, 2, 3, 4, 5 or 6;
- each R1 and R2 are independently —C(O)OR3, —C(O)N(R3)2, —P(O)(OR3)2, —OP(O)(OR3)2, —S(O)2R3, —S(O)2OR3, —S(O)2N(R3)2, or tetrazolyl;
- each R3 is independently —H or C1-C6 alkyl;
- R4 is —H, —C(O)OR3, —C(O)N(R3)2, —P(O)(OR3)2, —OP(O)(OR3)2, —S(O)2R3, —S(O)2OR3, —S(O)2N(R3)2, or tetrazolyl;
- L is —P(O)(OR3)—, or —P(O)(N(R3)2)—;
- M and T are independently —O—, —S—, —N(R3)—, or —CH2—;
- R7 is —X—R8 or —L1—R8, wherein
- X is —O—, —S—, or —N(R3)—;
- L1 is —C(O)N(R3)—, —C(S)N(R3)—, —C(O)CH(R21)—, —C(O)(O)—, —C(O)—L2—, a peptide, dendrimer, or peptide dendrimer, wherein
- R21 is —H, aryl, heteroaryl, C1-C6 alkyl-aryl optionally substituted with —OH;
- C1-C6 alkyl-heteroaryl, or C1-C6 alkyl optionally substituted with —OR23, —SR23, —NH2, —N(H)C(═NH)NH2, —COOR23, or —C(O)N(R23)2;
- and
- R23 is —H, C1-C6alkyl, or C1-C6 alkyl-aryl;
- L2 is —C1-C24 alkyl- or -phenyl-C1-C24 alkyl-, wherein
- each alkyl group is optionally substituted with 1 to 4 groups which are oxo, ═S, or —COOH;
- and
- one to six of the methylene groups in each alkyl group is optionally replaced by —O—, —S—, or —N(R3)—, provided that no two adjacent methylene groups are both replaced by —O—, —S—, or —N(R3)—;
- and
- R8 is a therapeutic agent, detectable label, or biomolecular anchor linked to a solid support;
- and
- Q is —O—, —S—, —N(R3)—, —N(R3)O—, —ON(R3)—, —CH2—, or ═NO—.
19 more elements
Dependencies are inferred from the claim text.